Open Access

Sericin enhances the insulin‑PI3K/AKT signaling pathway in the liver of a type 2 diabetes rat model

  • Authors:
    • Chengjun Song
    • Donghui Liu
    • Songhe Yang
    • Luyang Cheng
    • Enhong Xing
    • Zhihong Chen
  • View Affiliations

  • Published online on: August 17, 2018     https://doi.org/10.3892/etm.2018.6615
  • Pages: 3345-3352
  • Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the current study was to investigate the regulatory effect of sericin on the hepatic insulin‑­phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT) signaling pathway in a type 2 diabetes rat model. Male Sprague Dawley rats were randomly divided into four groups: Control group, diabetic model group, high‑dose sericin group and low‑dose sericin group, with 12 rats in each group. Fasting blood glucose was detected by the glucose oxidase method, and hepatic glycogen was determined by periodic acid‑Schiff staining. The morphology of the liver was observed by hematoxylin and eosin staining. Immunohistochemical staining, western blotting and reverse transcription‑quantitative polymerase chain reaction were used to determine the protein and mRNA expression levels of insulin receptor (IR), IR substrate‑1 (IRS‑1), PI3K and AKT. Compared with the control group, the blood glucose of the diabetic model group was significantly increased (P<0.05). The glycogen content and the expression levels of IR, IRS‑1, PI3K and AKT in the diabetic model group were significantly lower (P<0.05), and the liver morphological structure of the diabetic model group exhibited obvious pathological changes compared with the control group. Compared with the diabetic model group, the blood glucose of the high‑ and low‑dose sericin groups was significantly reduced, while the glycogen content and the expression levels of IR, IRS‑1, PI3K and AKT in the sericin treatment groups were significantly increased (P<0.05). Additionally, the liver pathological changes of high‑dose and low‑dose sericin groups were markedly reduced. Sericin may enhance the signaling transduction effect of insulin by upregulating the expression levels of key factors (IR, IRS‑1, PI3K and AKT) in the liver insulin‑PI3K/AKT signaling pathway, thus promoting glucose transport and liver glycogen synthesis, and further reducing blood glucose.
View Figures
View References

Related Articles

Journal Cover

October-2018
Volume 16 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Song C, Liu D, Yang S, Cheng L, Xing E and Chen Z: Sericin enhances the insulin‑PI3K/AKT signaling pathway in the liver of a type 2 diabetes rat model. Exp Ther Med 16: 3345-3352, 2018
APA
Song, C., Liu, D., Yang, S., Cheng, L., Xing, E., & Chen, Z. (2018). Sericin enhances the insulin‑PI3K/AKT signaling pathway in the liver of a type 2 diabetes rat model. Experimental and Therapeutic Medicine, 16, 3345-3352. https://doi.org/10.3892/etm.2018.6615
MLA
Song, C., Liu, D., Yang, S., Cheng, L., Xing, E., Chen, Z."Sericin enhances the insulin‑PI3K/AKT signaling pathway in the liver of a type 2 diabetes rat model". Experimental and Therapeutic Medicine 16.4 (2018): 3345-3352.
Chicago
Song, C., Liu, D., Yang, S., Cheng, L., Xing, E., Chen, Z."Sericin enhances the insulin‑PI3K/AKT signaling pathway in the liver of a type 2 diabetes rat model". Experimental and Therapeutic Medicine 16, no. 4 (2018): 3345-3352. https://doi.org/10.3892/etm.2018.6615